Literature DB >> 23443447

Defining diastolic heart failure and identifying effective therapies.

John G F Cleland, Pierpaolo Pellicori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23443447     DOI： 10.1001/jama.2013.1569

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  9 in total

1.  Heart failure with mid-range ejection fraction and with preserved ejection fraction.

Authors:  J Petutschnigg; F Edelmann
Journal:  Herz       Date:  2018-08       Impact factor: 1.443

2.  Fluid Management in Patients with Chronic Heart Failure.

Authors:  Pierpaolo Pellicori; Kuldeep Kaur; Andrew L Clark
Journal:  Card Fail Rev       Date:  2015-10

3.  Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification?

Authors:  Pierpaolo Pellicori; Anna Kallvikbacka-Bennett; Olga Khaleva; Valentina Carubelli; Pierluigi Costanzo; Teresa Castiello; Kenneth Wong; Jufen Zhang; John G F Cleland; Andrew L Clark
Journal:  Int J Cardiovasc Imaging       Date:  2013-10-23       Impact factor: 2.357

4.  [Heart failure with preserved left ventricular ejection fraction].

Authors:  Johannes Petutschnigg; Frank Edelmann
Journal:  Internist (Berl)       Date:  2019-09       Impact factor: 0.743

Review 5.  Epidemiology of heart failure with preserved ejection fraction.

Authors:  Charlotte Andersson; Ramachandran S Vasan
Journal:  Heart Fail Clin       Date:  2014-07       Impact factor: 3.179

6.  Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial.

Authors:  Gerasimos Filippatos; John R Teerlink; Dimitrios Farmakis; Gad Cotter; Beth A Davison; G Michael Felker; Barry H Greenberg; Tsushung Hua; Piotr Ponikowski; Thomas Severin; Elaine Unemori; Adriaan A Voors; Marco Metra
Journal:  Eur Heart J       Date:  2013-12-06       Impact factor: 29.983

7.  Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction.

Authors:  Frank Edelmann
Journal:  ESC Heart Fail       Date:  2015-05-06

8.  Detection and Management of Geographic Disparities in the TOPCAT Trial: Lessons Learned and Derivative Recommendations.

Authors:  Michael R Bristow; Jorge Silva Enciso; Bernard J Gersh; Christine Grady; Madeline Murguia Rice; Steven Singh; George Sopko; Robin Boineau; Yves Rosenberg; Barry H Greenberg
Journal:  JACC Basic Transl Sci       Date:  2016-04

9.  Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA.

Authors:  Mohamed Faher Almahmoud; Elsayed Z Soliman; Alain G Bertoni; Bryan Kestenbaum; Ronit Katz; João A C Lima; Pamela Ouyang; P Elliott Miller; Erin D Michos; David M Herrington
Journal:  J Am Heart Assoc       Date:  2018-09-18       Impact factor: 5.501
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.